Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in CAR-T Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice
  • CME

Credits Available
Physicians: maximum of 2.25 AMA PRA Category 1 Credits
Released: January 13, 2022 Expiration: January 12, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb
Michael R. Bishop, MD
Program Director
person default
Jesús G. Berdeja, MD
Jae H. Park, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate into practice up-to-date efficacy and safety data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Discuss considerations associated with CAR T-cell therapy, including patient selection, referring patients to specialized centers, and the importance of collecting patient-reported outcomes
  • Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Michael R. Bishop, MD

Professor of Medicine
Section of Hematology/Oncology
Director, Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has disclosed that he has received consulting fees and funds for research support from Arcellx, Autolus, Bristol-Myers Squibb, CRISPR, Kite/Gilead Sciences, and Novartis and fees for non-CME/CE services from Bristol-Myers Squibb and Kite/Gilead Sciences.

Faculty

Jesús G. Berdeja, MD

Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Jesús G. Berdeja, MD, has disclosed that he has received consulting fees from Bluebird Bio, Bristol-Myers Squibb, Celgene, CRISPR, Janssen, Kite, Legend, SecuraBio, and Takeda and funds for research support (to his institution) from AbbVie, Acetylon, Amgen, Astex, Bluebird Bio, Bristol-Myers Squibb, Celator, Celgene, Celularity, CRISPR, CURIS, EMD Serono, Genentech, GlaxoSmithKline, Ichnos, Incyte, Janssen, Juno, Kesios, Lilly, Millennium, Novartis, Onyx, Pharmacyclics, Poseida, Sanofi, Takeda, and Vivolux.
Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Jae H. Park, MD, has disclosed that he has received consulting fees from Allogene, Amgen, AstraZeneca, Autolus, GlaxoSmithKline, Kite, Novartis, and Takeda.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 13, 2022, through January 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Advances in CAR-T Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice
  • CME

Loading...
In this on-demand webcast of a live satellite symposium, expert faculty review the latest safety and efficacy data on CAR T-cell–based therapies for leukemias, lymphomas, and myeloma.
Michael R. Bishop, MD
Program Director
person default
Jesús G. Berdeja, MD
Jae H. Park, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits
Released: January 13, 2022 Expiration: January 12, 2023

Related Content

Commentary on current molecular testing and biomarker-guided care in NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Released: May 26, 2022

Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 19, 2022 Expired: May 18, 2023

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings